

REMARKS

By this amendment, the priority information in the specification was updated and a table in paragraph [00159] was amended to include SEQ ID Nos associated with some of the compound numbers in the table. The SEQ ID Nos added to the table are found in paragraph [0052] at pages 28-30 of the specification. Accordingly, no new matter has been added with this amendment.


With respect to all amendments, Applicants have not dedicated or abandoned any unclaimed subject matter, and moreover, have not acquiesced to any rejections or objections made by the Patent Office. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).

No additional fees are believed due for this submission. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

Dated: August 10, 2006

By: 
Karen R. Zachow, Ph.D.
Reg. No. 46,332

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Phone: (858) 552-2200
Facsimile: (858) 552-1936